ImmunityBio Inc. Stock
ImmunityBio Inc. Stock
Pros and Cons of ImmunityBio Inc. in the next few years
Pros
Cons
Performance of ImmunityBio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ImmunityBio Inc. | 40.150% | 77.322% | 82.094% | 47.475% | 95.648% | -22.517% | -76.071% |
| Ardelyx Inc. | -3.030% | 0.999% | 15.023% | 17.020% | 23.453% | 108.851% | 6.125% |
| Evolus Inc | -0.470% | -12.448% | -27.241% | -56.269% | -22.569% | -46.242% | -11.826% |
| Champions Oncology Inc | 2.560% | 4.464% | 5.405% | 22.899% | 0.862% | 46.985% | -35.714% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of ImmunityBio, a company operating in the Biotechnology & Medical Research sector, the overall impression is that of a company grappling with significant challenges. Key metrics such as earnings, profitability, and valuation ratios suggest a period of struggle, which may be indicative of a firm still in the development stages of its products. This analysis aims to break down both the merits and downfalls of the current financial landscape to better understand ImmunityBio's potential trajectory.
Market Capitalization
Revenue Generation
Comments
News
Why ImmunityBio Stock Is Skyrocketing Again Today
Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (NASDAQ: IBRX), spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%
ImmunityBio (NASDAQ:IBRX), a cancer and infectious-disease drug developer, closed Thursday at $3.95, up 30.79% for the session. The stock jumped after preliminary 2025 results highlighted roughly
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know
Heights Capital Management recently established a new position in ImmunityBio (NASDAQ:IBRX), buying 6,565,709 shares valued at approximately $16.15 million.
Heights Capital Management disclosed a